de Llano LAP, Cosío BG, Domingo C, et al. - Researchers undertook this 24-week prospective, multicenter, open-label, single-group, self-controlled study to assess whether weight-based intravenous reslizumab dosing is safe and efficacious in patients who have previously failed therapy with omalizumab. They looked for any significant improvement in asthma symptoms evaluated by the Asthma Control Test (ACT) at week 24 after treatment with reslizumab in 29 patients (62.1% women, median age, 50.8 years). From baseline to 24 weeks, a significant increase in the median ACT score from 13.0 to 21.0 was noted. At least 1 severe exacerbation was reported in only 2 of 29 patients during follow-up and none of them needed hospitalization. A significant reduction from 72.4% to 52.0% in the percentage of patients who were taking daily systemic corticosteroids was observed. Mostly, the adverse events observed were moderate and were within the range of earlier reported side effects with reslizumab. Findings revealed the efficacy as well as the safety of reslizumab as a treatment option for patients with severe eosinophilic asthma and a history of omalizumab failure.